Comparing Effectiveness of Aripiprazole Augmentation, rTMS Augmentation, and Switching to Venlafaxine XR in Treatment Resistant Depression (ASCERTAIN-TRD)
Brief description of study
This is a multi-site, randomized, open-label, to compare the efficacy of aripiprazole augmentation, rTMS augmentation, and switching to venlafaxine XR as treatments for treatment-resistant depression.
Detailed description of study
Subjects will be randomized to one of three treatment arms: a) aripiprazole added to the current antidepressant, b) rTMS added to the current antidepressant, and c) switching to venlafaxine XR. All subjects will be followed for 8 weeks to examine the efficacy of the study treatments.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Depression, Major depression, Depression, depression
-
Age: Between 18 Years - 80 Years
-
Gender: All
Updated on
07 Jul 2023.
Study ID: TX4803
